BioNTech Results Presentation Deck

BNT311 Phase 1/2: First-in-Human Study of DuoBody-PD-L1x4-1BB Next Generation Immunomodulator designed to prime and activate anti-tumor T cell and NK cell function via Mechanism of action of FC-silenced DuoBody-PD-L1x4-1BB T Cell PD-L1 blockade and Conditional 4-1 BB stimulation 19 TCR 4-1BB MHC-1/11 PD-L1* (tumor cell/APC) PD-1 DuoBody-PD-L1x4-188 PD-L1 DuoBody-PD-L1x4-1BB Tumor Cell Antigen-presenting cell T cell Myeloid cell Natural Killer cell Macrophage LOCAL LYMPH NODES NK TUMOR SITC 2021 Peripheral and Tumoral Immunologic Responses Supportive of Proposed Mechanism of Action in CPI-experienced NSCLC Patients ● ● Program partnered with Genmab; 50:50 profit/loss NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; NK cell, natural killer cell; CPI, checkpoint inhibitor PD-L1 Inhibitor-Pre-treated patients 25 NSCLC patients with evaluable baseline tumors Best relative change in sum of diameters from baseline, % ● 40 20 -20- -40- -60- Im PD-L1+ PD-L1- Patients with tumor reduction mainly PD-L1+ tumors Tumor reduction in 7 of 11 patients with PD-L1+ tumors Patient selection by PD-L1 status and combination with anti-PD-L1 may improve efficacy of BNT311 BIONTECH Y

View entire presentation